CAR T cells targeting CD19 or B cell maturation antigen (BCMA) are FDA approved for the treatment of relapsed/refractory B cell lymphoma/leukemia and multiple myeloma, respectively, following high rates of complete responses during clinical trials [3,4,5,6,7,8,9,10]. This evidence concerns the gene TNFRSF17 and plasma cell myeloma.